Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Atrial fibrillation drugs get committee review

Executive Summary

FDA's Cardio-Renal Drugs Advisory Committee will review two new chemical entities for acute conversion of atrial fibrillation Dec. 11-12, Cardiome/Astellas' vernakalant and Solvay's Pulzium (tedisamil), according to Cardiome. The meeting date comes after vernakalant's user fee date, necessitating a three-month user fee extension to Jan. 19. Executives at Cardiome indicated the decision was likely due to the agency's decision to put Solvay's competing product - submitted months after the NDA for vernakalant had been filed - under an advisory committee review. Cardiome submitted its NDA for an intravenous version of vernakalant in December, while Solvay announced its NDA filing for an IV Pulzium formulation in April...
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS048738

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel